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Soft selective eventMolecular surveillance provides a powerful approach to monitoring the resistance status of parasite pop-
ulations in the field and for understanding resistance evolution. Oxamniquine was used to treat Brazilian
schistosomiasis patients (mid-1970s to mid-2000s) and several cases of parasite infections resistant to
treatment were recorded. The gene underlying resistance (SmSULT-OR) encodes a sulfotransferase
required for intracellular drug activation. Resistance has a recessive basis and occurs when both
SmSULT-OR alleles encode for defective proteins. Here we examine SmSULT-OR sequence variation in a
natural schistosome population in Brazil 40 years after the first use of this drug. We sequenced
SmSULT-OR from 189 individual miracidia (1–11 per patient) recovered from 49 patients, and tested pro-
teins expressed from putative resistance alleles for their ability to activate oxamniquine. We found nine
mutations (four non-synonymous single nucleotide polymorphisms, three non-coding single nucleotide
polymorphisms and two indels). Both mutations (p.E142del and p.C35R) identified previously were
recovered in this field population. We also found two additional mutations (a splice site variant and
1 bp coding insertion) predicted to encode non-functional truncated proteins. Two additional substitu-
tions (p.G206V, p.N215Y) tested had no impact on oxamniquine activation. Three results are of particular
interest: (i) we recovered the p.E142del mutation from the field: this same deletion is responsible for
resistance in an oxamniquine selected laboratory parasite population; (ii) frequencies of resistance alleles
are extremely low (0.27–0.8%), perhaps due to fitness costs associated with carriage of these alleles; (iii)
that four independent resistant alleles were found is consistent with the idea that multiple mutations can
generate loss-of-function alleles.
 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction are now widely used for tracking resistance in malaria (PearceSurveys of drug resistance alleles using molecular markers pro-
vide a powerful approach to identify pathogen populations in
which resistance is emerging, to map resistance spread, and for
evidence-based resistance management. Molecular approacheset al., 2009; Ashley et al., 2014), HIV (Panichsillapakit et al.,
2015) and bacterial diseases (Bhembe et al., 2014), and for manag-
ing insecticide resistance (Essandoh et al., 2013; Djègbè et al.,
2014). Such methods are also now actively used for monitoring
resistance in helminths of veterinary importance such as
Haemonchus contortus (Rufener et al., 2009; Chaudhry et al.,
2015; Redman et al., 2015), and have enormous potential for mon-
itoring resistance in helminth parasites infecting humans, because
existing phenotypic screening methods based on reductions in pro-
duction of eggs or larval stages are insensitive for detection of low
frequency resistance alleles and cannot detect recessive resistance
alleles present in heterozygous worms. However, molecular
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identified, which is rarely the case for human helminth infections
such as schistosomiasis.
Schistosomiasis, caused by three major species of blood flukes
of the genus Schistosoma (Dye et al., 2013; Colley et al., 2014), is
the second most important tropical parasitic disease after malaria
(Steinmann et al., 2006), affecting an estimated 260 million people
across Africa, Asia and South America, and killing over 200,000
people per year. Two drugs are available for treating schistosomi-
asis. Praziquantel (PZQ) is currently used as a monotherapy in
expanding mass drug administration programs in Africa (Dye
et al., 2013), making resistance evolution a major concern. A sec-
ond drug, oxamniquine (OXA), is the focus of this paper. OXA acts
specifically against Schistosoma mansoni, which is found in Africa,
together with Schistosoma haematobium, and in South America,
where it is the only species present. OXA was manufactured in Bra-
zil by Pfizer (Cheetham, 1994) and widely used to treat S. mansoni
infections from the mid-1970s to the mid-2000s (Coura and
Amaral, 2004), but has now been replaced by PZQ as the first line
drug.
Schistosomes resistant to OXA were first identified in Brazil in
1973 (Katz et al., 1973a,b), around the same time as the first clinical
study of OXA treatment (Katz et al., 1973a,b). This rapid emergence
of resistance was most likely due to the previous treatment of the
same populations with the related drug hycanthone (Katz et al.,
1968; Coura and Conceicão, 2010), as both OXA and hycanthone
have the same target (Jansma et al., 1977; Pica-Mattoccia et al.,
1993) and the same mechanism of resistance (Pica-Mattoccia
et al., 1992a). Later genetic studies showed that resistance is a
recessive single locus trait (Cioli and Pica-Mattoccia, 1984; Pica-
Mattoccia et al., 1993), most likely involving the absence of a sulfo-
transferase activity necessary for drug activation in resistant schis-
tosomes (Pica-Mattoccia et al., 2006). The gene encoding the
S. mansoni sulfotransferase involved in OXA resistance (SmSULT-OR)
was recently identified by classical quantitative trait mapping in
concert with crystallographic and functional analyses (Valentim
et al., 2013). This work identified an amino acid deletion (p.
E142del) in the laboratory-selected resistant parasite (HR), while
an independent loss-of-function mutation (p.C35R) was identified
in a field-collected resistant parasite line (MAP).
The identification of the gene involved in OXA resistance now
allows us to examine distribution of resistance alleles of SmSULT-
OR in natural populations. Despite the fact that the Brazilian gov-
ernment has switched from OXA to PZQ during the last decade
(Utzinger et al., 2003), the recessive nature of OXA resistance
allows the persistence of these alleles, because alleles encoding
non-functional enzyme are not counter-selected as long as they
segregate with alleles encoding a functional enzyme. We collected
miracidia larval stages from a village in Minas Gerais, Brazil, and
sequenced the SmSULT-OR gene in these samples. We sought to
answer several questions: How common are resistance alleles?
How many times have OXA resistance alleles arisen? Are the
OXA resistance alleles selected in the laboratory and identified
using linkage mapping actually present in nature? More broadly,
our goal is to better understand the evolution of drug resistance
in schistosomes and to demonstrate the utility of molecular
screening approaches in anticipation that the gene(s) underlying
PZQ resistance will soon be identified.2. Materials and methods
2.1. Ethics statement
Stool samples were collected in accordance to the procedures of
the Research Ethics Committee of the Universidade Federal de SãoPaulo, Brazil (process number CAAE: 15567313.8.0000.5091). The
purpose of the study and the procedures to be followed were
explained and written informed consent was obtained from all par-
ticipants or their legal guardians prior to any collection.
2.2. Sampling of S. mansoni miracidia
We collected stools from school children from Ponto dos
Volantes (Minas Gerais, Brazil, GPS coordinates: 164503.30100 S,
4130013.75500W) and shipped these at 4 C by ground transporta-
tion overnight to the Universidade Federal de Minas Gerais in Belo
Horizonte, Brazil. We processed samples as follows: several grams
of stools were filtered through three layers of sieves (mesh size:
250–45 lm) to obtain schistosome eggs. Eggs were transferred
from the third sieve grid to a Petri dish and exposed under artificial
light for at least 1 h. All filtering steps and egg transfer were per-
formed with locally available bottled mineral water.
Washed eggs were observed under a stereomicroscope. For each
patient, 1–11 living miracidia were sampled individually in 2 lL
of water and spotted onto CloneSaver FTA cards (GE Healthcare Life
Sciences, USA). Spotted samples can be easily located on the cards
because the pink dye on the cards turns white after water contact.
Full cards were allowed to dry for 1 h at room temperature on the
bench before being stored in a plastic bag and finally shipped to
San Antonio, Texas, USA.
2.3. Preparation of FTA samples for whole genome amplification
(WGA)
For each sample, we removed a 2 mm diameter disc from the
FTA card using a 2 mm Harris Micro-punch (GE Healthcare Life
Sciences). The 2 mm disc corresponds to the entire spot containing
the whole miracidium. Each punch was placed individually in a
1.5 mL sterile tube. Punches were washed three times with FTA
Purification Reagent (GE Healthcare Life Sciences) then rinsed
twice with TE1 buffer (10 mM Tris, 0.1 mM EDTA, pH 8). Washing
and rinsing steps were performed by adding 200 lL of solution to
each tube followed by 5 min of incubation on a nutating mixer
(24 RPM) at room temperature and then discarding the solution
while minimising contact between the pipette tip and the punch.
Punches were finally dried in tubes for 10 min at 56 C on a dry
bath incubator.
2.4. WGA
We performed WGA on each punch using the illustra Genomi-
Phi V2 DNA Amplification kit (GE Healthcare Life Sciences).
Punches were transferred in 0.2 mL sterile tubes using a sterile
tip. We performed reactions following the manufacturer’s instruc-
tions, immersing each punch in 9 lL of sample buffer and keeping
tubes on ice at all times after the denaturation step. After amplifi-
cation, we quantified DNA using the Qubit dsDNA BR assay
(Invitrogen, USA).
2.5. Sequencing of SmSULT-OR exons
The two exons of the SmSULT-OR gene were amplified and
sequenced independently. Each PCR was performed using the
TaKaRa Taq kit (Clontech, USA) and composed of 9.325 lL of sterile
water, 1.5 lL of 10 buffer, 1.2 lL of dNTP (2.5 mM each), 0.9 lL of
MgCl2 (25 mM), 0.5 lL of each primer (10 lM; Table 1), 0.075 lL of
Taq polymerase (5 UlL1) and 1 lL of DNA template. Amplifica-
tions were done using a GeneAmp PCR system 9700 thermocycler
(Applied Biosystems, USA) with the following program: 95 C for
5 min; 95 C for 30 s, 60 C for 30 s, 72 C for 45 s, for 35 cycles;
then 72 C for 10 min.
Table 1
Primer sequences used for PCRs and sequencing of the two exons of the Schistosoma mansoni SmSULT-OR gene in this study.
Primer type Primer sequence (50–30 orientation) Expected amplicon size (bp) Usage
Exon 1 Outer forward primer GCGAGATTCAAACCCAGGAT 822 PCR
Outer reverse primer GCCGTGATATTACTATCAATCCC PCR
Nested forward primer GGGTAAAGGAAGAGGGTTGG 545 PCR
Nested reverse primer TAAGAACAGACATATTAGACGAGT PCR and sequencing
Sequencing forward primer TATATATGAAATATTATAACATTAC – Sequencing
Exon 2 Forward primer ACTTCAACCAATCCACAAATCC 672 PCR and sequencing
Reverse primer AGTCCATTCATTCAATGTTTCAA PCR and sequencing
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uct. Products from the first PCR were cleaned up by adding 4 lL of
ExoSAP-IT (Affymetrix USB products, USA). Tubes were then incu-
bated at 37 C for 30 min and at 80 C for 15 min using a thermo-
cycler. Cleaned PCR products were then used as templates for the
second PCR following the above protocol.
Sequencing reactions were performed using a BigDye Termi-
nator v3.1 cycle sequencing kit (Applied Biosystems) on final PCR
products. PCR products were cleaned up using ExoSAP-IT as
described above. Sequencing reactions were performed using
2.59 lL of sterile water, 1 lL of 5 running buffer, 0.25 lL of Big-
Dye Terminator ready reaction mix (Applied Biosystems), 0.16 lL
of forward or reverse primer used in the final PCR step, and 1 lL
of final PCR product. Sequencing fragments were generated using
a GeneAmp PCR system 9700 thermocycler (Applied Biosystems)
with the following program: 96 C for 1 min; 96 C for 10 s, 50 C
for 5 s, 60 C for 4 min, for 25 cycles. Sequencing reactions were
cleaned up using a BigDye XTerminator purification kit (Applied
Biosystems). In each reaction, 20.45 lL of SAMTM solution and
4.55 lL of XTerminatorTM solution were added. Reactions were then
vortexed for 30 min and run on a 3730xl DNA Analyzer (Applied
Biosystems).
Sequencing files were first screened using FinchTV (v1.4.0;
Geospiza Inc.) to identify failed sequencing reactions. In the case
of failure, sequencing reactions were performed a second time.
2.6. Variant identification and functional impact evaluation
We scored variants using PolyPhred software (v6.18)
(Nickerson et al., 1997) which relies on Phred (v0.020425.c), Phrap
(v0.990319), and Consed (v29.0) software, analysing each exon
independently. We identified single nucleotide polymorphisms
using a minimum phred quality score (-q) of 40, a minimum geno-
type score (-score) of 90, and a reference sequence that includes
the SmSULT-OR gene and surrounding regions (position 1519500
to 1525200 of chromosome 6 of S. mansoni reference genome
v5.0, ftp://ftp.sanger.ac.uk/pub/pathogens/Schistosoma/mansoni/
genome/Assembly-v5/sma_v5.0.chr.fa.gz). Variant sites were
labelled as non-reference alleles if they differed from the reference
sequence. We identified insertion/deletion (indel) polymorphisms
using a minimum phred quality score (-q) of 40 and a minimum
genotype score (-iscore) of 80. Polymorphisms were visually vali-
dated using Consed. All the sequences were submitted to GenBank
(GenBank accession no KU951903–KU952091).
Nucleic sequences showing mutations were translated in silico
into protein sequences using the Translate tool from ExPASy portal
(Artimo et al., 2012).
We evaluated the potential functional impact of identified poly-
morphisms on RNA features and on protein structure in silico.
Modifications of RNA motifs and sites were analysed using the
RegRNA2.0 website (Chang et al., 2013) for all available features
with Drosophila melanogaster as the reference species when
required. Modifications in protein structure were assessed using
the mutagenesis function of PyMol software (v1.7.2.0; Schrödinger,LLC) using the structure of SmSULT-OR determined previously
(PDB code 4MUB, Valentim et al., 2013).
2.7. Population genetics analysis
We evaluated population structure by testing for Hardy–
Weinberg equilibrium, measuring fixation indices (Fst and Fis) of
parasites using Genepop (Rousset, 2008) with default options
and considering schistosomes from a given patient as belonging
to the same population. To identify positive selection, we calcu-
lated the number of synonymous (s) and non-synonmous (n) sites
(Nei and Gojobori, 1986) and compared these values to synony-
mous (S) and non-synonymous (N) changes. We also performed
a McDonald-Kreitman (MKT) test using the MKT server (http://
mkt.uab.es; Egea et al., 2008). The SmSULT-OR homologue
sequence in Schistosoma rodhaini was used as an outgroup and
was obtained using tblastx from the NCBI server (NCBI Resource
Coordinators, 2015) on the S. rodhaini genome assembly
(GenBank accession no. GCA_000951475.1) using the SmSULT-OR
sequence (GenBank accession no. KF733459.1) as a query.
2.8. Recombinant SmSULT-OR protein production
The SmSULT-OR sequence from the reference genome
(Smp_089320; GenBank accession no. HE601629.1) was used to
create a codon optimised synthetic gene (GenScript, USA) which
was subcloned into the pAG8H vector derived from pKM260
(Melcher, 2000). We introduced mutations using a Phusion site-
directed mutagenesis protocol (ThermoFisher Scientific, USA).
Transformed Escherichia coli strain BL21 pLysS (Promega) were
grown at 37 C until the absorbance (k = 600 nm) reached 0.7.
We then decreased the temperature to 18 C and induced expres-
sion by the addition of isopropyl-b-D-thiogalactoside (IPTG) at a
final concentration of 1 mM. The cells were washed and resus-
pended in 50 mL of 50 mM Tris pH 8.0, 500 mM NaCl (column buf-
fer) containing 250 lL of Sigma protease inhibitor cocktail per litre
of culture and lysed by sonication on ice. The clarified supernatant
was loaded onto a Ni2+-NTA affinity chromatography column (GE
Healthcare), washed with five volumes of column buffer, and
eluted using a 10–500 mM imidazole gradient. We pooled fractions
identified as the Smp_089320 via SDS–PAGE and added His-tagged
Tobacco etch virus (TEV) protease at a Smp_0893230:protease
ratio of 15:1. The resulting solution was dialyzed overnight at
4 C against 50 mM Tris pH 8.0, 100 mM NaCl, 2 mM dithiothreitol
(DTT). We passed the dialysate over the Ni2+-NTA column again to
remove the His tag and the His-tagged TEV protease, while the
cleaved target protein flowed through. The sample was loaded onto
a GE-pre-packed Q anion exchange column and eluted with a 0.1–
1.0 M NaCl gradient. We pooled fractions containing Smp_089320
as identified by SDS–PAGE and dialyzed overnight at 4 C against
25 mM Tris pH 8.5, 50 mM NaCl, 2 mM reducing agent
tris-(carboxyethyl)-phosphine (TCEP) to prevent formation of
intermolecular disulphide bonds. The product was 98% pure as
estimated by SDS–PAGE. We concentrated the purified
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tion coefficient e = 39,880 mol1cm1.2.9. OXA activation assay
This assay utilises the fact that OXA is a prodrug that is enzy-
matically converted into a highly reactive molecule that covalently
binds intracellular components such as DNA (Pica-Mattoccia et al.,
1989). Because the original assay employs worm extracts which
require time for preparation and introduce unpredictable varia-
tions in SmSULT-OR concentration (Pica-Mattoccia et al., 1992a;
Valentim et al., 2013), we developed an improved in vitro assay
that uses purified recombinant SmSULT-OR enzyme. This in vitro
assay measures the enzymatic sulphonation of tritiated OXA mole-
cules which then bind genomic DNA (gDNA). The resultant
radioactive DNA-OXA complexes can then be quantified by a scin-
tillation counter. Enzymes produced by non-functional SmSULT-OR
alleles cannot sulphonate OXA, so no DNA-OXA complexes are
formed.
Recombinant proteins were expressed and purified commer-
cially by GenScript (p.C35R, p.P67L, p.E142del; Valentim et al.,
2013) or by the Hart laboratory (University of Texas Health Science
Center, USA) (p.G206V and p.N215Y). To determine which recom-
binant protein has the ability to activate OXA, 1 nM from each
recombinant protein was added to 90 lL of a protease inhibitor
cocktail (PIC) consisting of 0.1 M HEPES pH 7.4, 0.1 mM leupeptin,
2 lM E-64, 2 lM pepstatin A, 0.1 U of aprotinin, and 10 nglL1
sheared S. mansoni gDNA as a final target. For each reaction
100 lCi of 3H-OXA (Pica-Mattoccia et al., 1989) was solubilised
in 2 lL of DMSO and added to 10 lL of a mixture containing the
enzyme cofactors ATP and MgCl2 at 50 mM each, and 30-phosphoa
denosine-50-phosphosulfate (PAPS) at 1 mM. The radiolabelled
OXA and co-factor mix was then added to the PIC mix containing
the recombinant protein. The resulting reaction was incubated
for 2.5 h at 37 C and stopped by adding three volumes of 0.1%
SDS in 0.1 M sodium bicarbonate. The reaction was then extracted
three times with two volumes of dichloromethane and the aqueous
phase was counted in a liquid scintillation spectrometer (Beckman
LS 6500 Scintillation Counter, USA) for 10 min. We also measured a
blank solution (water) and the background scintillation. Blank and
background values were subtracted from sample values. We per-
formed three independent reactions for each recombinant protein.Table 2
Mutations scored in the exons, intron, and 30 untranslated regions (UTR) of the Schistosoma
Schistosoma rodhaini, the number of homozygous and heterozygous samples carrying th
frequency of the non-reference allele, the corresponding amino acid mutation, and the fu
Nucleic mutation Schistosoma
rodhaini
state
No. of
homozygous
samples for
non-reference
allele
No. of
heterozygous
samples for
non-reference
allele
Sam
size
Exon 1 c.103T>C T 0 1 183
c.200C>T C 169 12 183
c.214_215insA – 0 1 183
Intron g.328G>A G 1 0 179
Exon 2 c.424_426delGAA – 1 1 188
c.617G>T G 1 0 188
c.643A>T A 0 1 188
30 UTR g.4720C>T C 177 9 188
g.4741T>C T 2 8 188
The code used for nucleic mutations indicates the sequence type (c = coding, g = gene), th
delN = deletion of N). The code used for protein mutations indicates the sequence type (p
acid, and when frame shift (fs) occurs, the position of the stop codon (X) after the muta2.10. Statistical analysis
Statistical analyses were done using R (v3.1.3) (R Core Team,
2015). For synonymous and non-synonymous changes, data were
compared using a Fisher’s exact test. For the OXA activation assay,
the data were compared with a Welch t-test after testing for nor-
mality (Shapiro test, P > 0.05).3. Results
3.1. Brazilian samples
We collected 232 FTA preserved miracidium samples from 51
patients (range: 1–12, mean ± S.D.: 4.55 ± 3.65). We successfully
amplified DNA from 204 samples (87.93%) from 50 patients (range:
1–11, mean ± S.D.: 4.08 ± 3.26). Among the amplified samples, 189
from 49 patients (range: 1–11, mean ± S.D.: 3.86 ± 3.18) contained
schistosome DNA (92.65% of amplified samples, 81.47% of total
samples). Among the 189 samples, we sequenced exon 1 from
183 samples and exon 2 from 188 samples. All samples had at least
one exon sequenced (Supplementary Table S1).3.2. SmSULT-OR variants in a Brazilian schistosome population
We scored nine mutations: four non-synonymous single
nucleotide polymorphisms (SNPs), one insertion and one deletion
in the coding region, and three non-coding SNPs (Table 2, Supple-
mentary Table S1). The number of mutations in each exon (three in
exon 1 and three in exon 2) did not differ regarding the length of
the exon (327 bp and 447 bp, respectively) (Fisher’s exact test,
P = 0.7).
Among the seven SNPs, five (71.43%) were transitions and two
(28.57%) were transversions. Four of the SNPs were located in the
exonic region, two in exon 1 and two in exon 2. Three were present
at very low frequency (0.0027–0.0053) while one was present at
very high frequency (0.95). One SNP was identified at the first posi-
tion of the intron at a low frequency (0.0056). The two remaining
SNPs were found in the 30 untranslated region (UTR), one at high
frequency (0.96), and one at low frequency (0.03).
One insertion was identified in exon 1 while one deletion was
identified in exon 2, both at very low frequency (0.0027 and
0.0080, respectively).mansoni SmSULT-OR gene. For each mutation, the corresponding nucleotide found in
e non-reference allele, the number of samples sequenced (sample size), the allele
nctional impact are shown.
ple Frequency
of the non-
reference
allele
Amino acid
mutation
Functional impact
0.0027 p.C35R Misfolded protein (Valentim et al., 2013)
0.9563 p.P67L No effect (Valentim et al., 2013)
0.0027 p.T72NfsX5 Truncated protein with no active site
0.0056 p.V110IfsX3 Splicing site disrupted leading to truncated
protein with no active site
0.0080 p.E142del Impaired oxamniquine binding
(Valentim et al., 2013)
0.0053 p.G206V No effect (Fig. 2)
0.0027 p.N215Y No effect (Fig. 2)
0.9654 – –
0.0319 – –
e position, and the mutation type (X>Y = substitution of X by Y, insN = insertion of N,
= protein), the reference amino acid, the position, and finally the alternative amino
tion. For details about the nomenclature, see Ogino et al. (2007).
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homozygous states among the samples. Observing rare SNPs pre-
sent as homozygotes was surprising, suggesting population struc-
ture. The test for Hardy–Weinberg equilibrium showed a global
deficit in heterozygosity (P < 0.0001). This is likely due to a deficit
of heterozygous genotypes within host (Fis = 0.3251) rather than
due to population differentiation between infections
(Fst = 0.0153). Null alleles are not likely to explain the deficit. While
we had small numbers of samples for which WGA failed, SmSULT-
OR was successfully amplified from all samples for which WGA
was successful.
Due to the absence of the synonymous mutations which
precludes dN/dS calculation, we compared synonymous (S) and
non-synonymous (N) changes with synonymous (s) and non-
synonymous (n) sites to evaluate evidence for selection on
SmSULT-OR. This comparison reveals no differences (Fisher’s exact
test, P = 1) indicating that there was no evidence for selection. We
also tested directional evolution by performing a McDonald–
Kreitman test using the homologue sequence of SmSULT-OR from
S. rodhaini as an outgroup. We found no evidence for directional
evolution (v2 = 1.466, P = 0.225).3.3. Functional impacts of mutations
3.3.1. Non-coding variants
We evaluated the functional impacts of the polymorphisms
identified based on RNA features such as binding sites or splicing
or regulatory motifs (Table 2). The mutation g.649G>A was pre-
dicted to modify the unique splice donor site at the end of exon
1. The disruption of the splicing site leads to translation of the
beginning of the intron which ends four codons later due to theFig. 1. Mapping of the mutations on the gene sequence and structure of Schistosoma man
beige, respectively. Single nucleotide polymorphisms and insertion/deletion events ar
highlighted in black. (A) Linear representation of the SmSULT-OR gene showing the rel
Positions of mutations on the SmSULT-OR protein. Oxamniquine is represented in yellow
and spatial distortions are represented by red discs. For a more detailed view of the muintroduction of a stop codon. This results in a truncated protein
with no active site (Fig. 1, Supplementary Movie S1). Mutations
present on the 30 UTR were not predicted to be in any regulatory
sites.
3.3.2. Coding variants
All SNPs identified in the coding sequence of the gene were
non-synonymous, and derived mutations relative to the outgroup
S. rodhaini (Table 2). c.103T>C induced a substitution of cysteine
to arginine (p.C35R) leading to a misfolded protein as shown pre-
viously (Valentim et al., 2013) (Fig. 1). c.200C>T induced a substi-
tution of proline to leucine (p.P67L) and was previously found in
the OXA sensitive strain (Valentim et al., 2013) (Fig. 1); this muta-
tion therefore does not reduce enzyme activity. c.617G>T induced
a substitution of glycine to valine (p.G206V) which occurs close the
binding site of the PAPS co-factor and was previously observed in
field-collected OXA resistant strain (Valentim et al., 2013) but
was never tested. We postulated that this mutation may have a
potential detrimental effect on co-factor binding and finally
enzyme activity (Fig. 1, Supplementary Movie S1). The mutation
c.643A>T induced a substitution of asparagine to tyrosine (p.
N215Y) which occurs on a helix connected to a loop involved in
co-factor binding. This mutation is predicted to have little impact
on protein structure. We therefore postulated that this will not
change protein function (Fig. 1, Supplementary Movie S1).
3.3.3. Indels
Both indels have detrimental effects on the enzyme (Table 2).
The insertion c.214_125insA induces a frame shift leading to an
early stop codon six codons after the mutation. This frame shift
is predicted to produce a truncated enzyme with no active site.soni SmSUTL-OR sulfotransferase. Exon 1 and exon 2 are represented in orange and
e represented in cyan and magenta, respectively. Loss-of-function mutations are
ative position of the mutations and their translation in amino acid sequences. (B)
, 30-phosphoadenosine-50-phosphosulfate (PAPS) co-factor is represented in green,
tations on the structure and their functional impact, see Supplementary Movie S1.
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Fig. 2. Enzymatic activity of recombinant Schistosoma mansoni SmSULT-OR sulfo-
transferase expressed from different allelic variants. This in vitro oxamniquine
activation assay quantifies DNA-oxamniquine complexes by scintillation (counts
per min) (see Section 2.9). Bars show the mean of three replicates, while error bars
are S.E.M. Enzyme carrying loss-of-function mutations, such as p.C35 or p.E142del,
showed no oxamniquine activation, while two newly identified alleles (p.G206V
and p.N215Y) did not impair oxamniquine activation. *P < 0.05.
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analyses to disrupt OXA binding (Valentim et al., 2013).
3.4. OXA activation assay
We produced two recombinant SmSULT-OR enzymes carrying
the mutations p.G206V and p.N215Y in order to experimentally
test whether these two mutations impact OXA activation, resulting
in OXA resistance. We also tested known resistance alleles (p.C35R
and p.E142del) as controls. The newly identified alleles are able to
activate OXA as well as the reference allele (wild type) which does
not carry any of these mutations (Welch t-test, t < 1.55, P > 0.18)
while the known resistance alleles showed no activation as
expected (Welch t-test, t > 5.58, P < 0.021) (Fig. 2). Therefore the
two mutations tested (p.G206V and p.N215Y) did not disrupt co-
factor binding or otherwise interfere with enzymatic activity.
4. Discussion
SmSULT-OR sequences from 189 miracidia collected from 49
Brazilian patients revealed nine mutations, including both muta-
tions previously implicated in OXA resistance (Valentim et al.,
2013). We found the p.C35R mutation, previously identified in
the MAP strain. MAP was sampled from a patient living in a city
of São Paulo state, Brazil (Pica-Mattoccia et al., 1992b), the neigh-
bouring state of that from which our samples were collected
(Supplementary Fig. S1). This suggests that the allele has been
segregating in Brazilian parasite populations for more than
25 years. The second variant identified in the field, p.E142del,
was previously found in the HR laboratory strain, which was ini-
tially sampled from a Puerto-Rican patient and subsequently
selected with hycanthone in the laboratory (Cioli and Pica-
Mattoccia, 1984) (Supplementary Fig. S1). This mutation could
have arisen spontaneously in the laboratory. However, given that
laboratory schistosome lines are maintained as outbred popula-
tions, the simplest explanation is that this mutation was segregat-
ing within the parasite population originally established in the
laboratory. That we located this same deletion in two miracidia
from Brazil and a parasite line collected from Puerto-Rico suggests
that this allele may be widespread in schistosome populations
from the New World.It is not clear from our data whether the p.E142del seen in HR
and Brazilian field samples arose independently or has a single
origin. The HR p.E142del is found together with another mutation
(p.L256W) (Valentim et al., 2013), which is absent from the
p.E142del allele found in the Brazilian miracidia, providing some
evidence for independent origins. Similarly, MAP differs from
the Brazilian miracidia carrying the p.C35R mutation; while both
also carry p.P67L, MAP carries an additional p.G206V mutation.
Additional flanking SNP data will be required to critically test
whether the p.E142del and p.C35R OXA resistance mutations have
arisen a single time, or have multiple independent origins.
Laboratory selection is commonly used to explore the genetics
of pathogen resistance, but a concern with this approach is that
the mutations selected in the laboratory may poorly represent
those occurring in nature. That we identified the same mutations
in laboratory and field selected parasites is extremely encouraging,
because ongoing work to identify mutations involved in PZQ resis-
tance also utilises laboratory selected parasites (Couto et al., 2011).
We note that laboratory selection experiments with Plasmodium
also tend to identify the same genes and often the same mutations
that are observed in the field (Anderson et al., 2011), further vali-
dating this approach.
Besides the two known alleles, two of these new mutations,
c.214_215insA and g.328G>A, are predicted to confer OXA resis-
tance; both introduce premature insertion of a stop codon produc-
ing a protein without an active site. These mutations therefore add
two additional loss-of-function mutations that were probably
selected during the OXA treatment. That four independent muta-
tions are found in a single sampled parasite population is remark-
able. Multiple origins have previously been observed in the
evolution of resistance to benzimidazole drugs in the gastrointesti-
nal nematode Haemonchus (Redman et al., 2015). The number of
origins of resistance alleles is expected to depend on the size of
the parasite population and the rate at which mutation generates
resistant alleles (Messer and Petrov, 2013). In the case of H. contor-
tus, the enormous size of parasite populations is likely to be the
main driver, as only several specific mutations within b-tubulin
can confer resistance. In the case of OXA resistance, a high muta-
tion rate may be expected as the main driver, because multiple dif-
ferent mutations within SmSULT-OR can generate non-functional
proteins. It is also possible that OXA resistant alleles were present
within Brazilian S. mansoni populations prior to hycanthone or
OXA treatment. Such standing variation may even have been pre-
sent prior to the introduction of S. mansoni into South America.
Analysis of SmSULT-OR in African populations, where OXA was
not used extensively, will help answer this question.
Work on OXA resistance is simplified because we have an effec-
tive in vitro functional assay for screening allelic variants. The
assay we used is an improvement on those previously described
(Pica-Mattoccia et al., 1992a; Valentim et al., 2013), because worm
homogenates are replaced by recombinant SmSULT-OR proteins.
We identified two additional exon 2 substitutions (p.G206V, p.
N215Y): Structural analyses suggested that one of these mutations
(p.G206V) may disrupt OXA activation, by interfering with binding
of the co-factor (PAPS), while the other (p.N215Y) is likely to have
minimal impact on function. We were able to directly test these
predictions by performing OXA activation assays. These assays
demonstrated that neither mutation prevents OXA activation,
allowing us to reject our prediction for p.G206V and confirm our
prediction for p.N215Y. Hence, while structural studies are useful
for formulating hypotheses about the consequences of mutations,
functional assays are essential for critical testing of these
hypotheses.
The two last mutations were found in the 3’ UTR of the cDNA. In
silico analysis, using predictions based on Drosophila, did not reveal
regulatory sites in these regions, suggesting that these mutations
F.D. Chevalier et al. / International Journal for Parasitology 46 (2016) 417–424 423do not impact function. However, Drosophila may be a poor model
to use. When more information on SmSULT-OR regulatory regions
become available, new analyses of these two mutations may reveal
potential effects on mRNA stability or translation rate.
The allele frequency of all four OXA resistance alleles combined
is 3.8%, and only two parasites of 183 sampled (1%) are homozy-
gous and therefore expected to be phenotypically resistant. The
low frequency of the OXA resistance alleles can be explained by
two non-exclusive hypotheses. First, resistance alleles may have
remained at low levels even when OXA was the first line drug in
Brazil. Second, fitness costs associated with these alleles may have
driven reductions in allele frequency after the abandonment of
OXA treatment. However OXA resistance alleles still persist within
the populations in a heterozygous state, the cost being present
only when worms are homozygous for the defective alleles.
Whether there is a cost associated with OXA resistance is ques-
tionable because miracidia homozygous for resistance alleles were
found in the field in the present study. A previous study showed a
reduction in infectivity and egg production in OXA resistant para-
sites relative to the OXA sensitive populations from which they
were isolated (Cioli et al., 1992). However, this study suffers from
a methodological limitation, because resistant and sensitive labo-
ratory populations had different genetic backgrounds, complicat-
ing interpretation. Comparison of isogenic wildtype and
genetically manipulated resistant parasites, or analysis of fitness
in the progeny of a genetic cross between OXA resistant and sensi-
tive parasites would allow measurement of associated fitness
costs, while minimising confounding background effects.
New drugs are urgently needed for schistosome control because
treatment currently relies on widespread monotherapy with PZQ.
OXA is effective only against S. mansoni, but new OXA derivatives
are under active development, with the aim of making compounds
that are active against all three major schistosome species infect-
ing humans (Taylor et al., 2015). If such derivatives are to be
deployed clinically, understanding the capacity for resistance evo-
lution in schistosome populations is of critical importance. For
example, surveys of sequence variation in SmSULT-OR or the S.
haematobium homologue would be an important prerequisite for
field deployment of an OXA derivative active against both these
species in Africa.
Our results have both positive and negative implications for
field deployment of OXA derivatives. That multiple resistance alle-
les are present in a single parasite population suggests that resis-
tance alleles may evolve and spread rapidly. On the positive side,
existing resistance alleles are currently at extremely low fre-
quency. It will be essential that OXA derivatives are deployed with
appropriate partner drugs to minimise the rate of resistance evolu-
tion. We note that resistance to the antimalarial atovaquone was
observed in the first clinical trial of this drug (Looareesuwan
et al., 1996) and evolved de novo in different treated patients
(Musset et al., 2007). Yet this drug is widely and effectively used
with proguanil as a combination drug under the trade name
Malarone.
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